Results 201 to 210 of about 34,270 (263)

Identifying the Thermodynamic Driving Force of Metal Extraction by Hydrophobic Eutectic Solvents. [PDF]

ChemSusChem
Vaz ICM, Saldanha Pinheiro M, Olea F, Cirillo L, Mannucci G, Busato M, D'Angelo P, Santos R, Bastos M, Santos LMNBF, Coutinho JAP, Schaeffer N.   +11 more
europepmc   +1 more source

Mutant p53R273H disrupts PDPK1 homodimerization and contributes to PDPK1 activation

Molecular Oncology, EarlyView.
How mutant p53R273H drives AKT signaling is unclear. We show that p53R273H, but not wild‐type, directly binds PDPK1 via a mutation‐dependent conformational change. This interaction disrupts inhibitory PDPK1 homodimerization and enhances AKT phosphorylation.
Mei Chee Lim, Alvin Kunyao Guo, Yoko Itahana, Srinivasaraghavan Kannan, Valerie Goh, Mingmin Ong, Terina Yan Wen Tay, Weiying Ye, Sabhashina Radha Krishnan, Jun Nishiyama, Chandra S Verma, Koji Itahana   +11 more
wiley   +1 more source

The legally protected fungi and lichens in the EU. [PDF]

IMA Fungus
Janowski D.
europepmc   +1 more source

Targeting the EpCAM‐AXL axis to overcome drug resistance in lung cancer

Molecular Oncology, EarlyView.
Lung cancer cells often evade therapy by hijacking signaling pathways. We reveal that cleaved EpCAM (sEpCAM) stabilizes the oncogenic protein AXL, driving NF‐κB and STAT3‐mediated chemoresistance. This EpCAM‐AXL axis identifies a high‐risk patient subset with poor prognosis.
Alexa Guerrero‐Alba, Mark Shacker, Timothy P. Fleming, Michael A. Smith, Ross M. Bremner, Narendra V. Sankpal   +5 more
wiley   +1 more source

Immune remodeling and myeloid signature in the bone marrow niche of MYCN-driven neuroblastoma. [PDF]

BJC Rep
Embaie BT, Alchahin AM, Velentza L, Olsen TK, Gavriliuc IM, Mei S, Baryawno N.   +6 more
europepmc   +1 more source

Characterization of therapeutic antibodies targeting lymphatic and vascular resistance factor for the treatment of hypervascularized and highly metastatic cancers

Molecular Oncology, EarlyView.
LVRF (lymphatic and vascular resistance factor) is a VEGFA splice variant upregulated in response to anti‐angiogenic therapy that fosters tumor adaptation through enhanced vascularization, lymphangiogenesis, and metastatic dissemination. Targeting LVRF with fully human neutralizing antibodies disrupts these processes and limits resistant tumor growth ...
Marion David, Arthur Karaulic, Audrey Bennetot, Clémence Fournier, Quentin Odet, Arthur Gouraud, Isabelle Bourget, Cédric Gaggioli, Sandy Giuliano, Frédéric Luciano, Olivier Léger, Zaki Sellam, Gilles Pagès   +12 more
wiley   +1 more source

National immunisation recommendations: why country-specific evidence and context matter. [PDF]

Lancet Reg Health Eur
Schaefer R, Harder T, Sandmann F, Wichmann O.   +3 more
europepmc   +1 more source

The Italian Nanomedicine Platform (INP): national integration within the European nanomedicine ecosystem. [PDF]

Nanomedicine (Lond)
Tosi G, Rossi M, Calzà L, Valenza M, Quaglia F, Cavallaro G, Cauda V, Angeloni L, Bedoni M, Palumbo F, Pasut G.   +10 more
europepmc   +1 more source

Rational guest selection: a general principle for stabilizing multi-component luminescent materials. [PDF]

Chem Sci
Jing LK, Chang YY, Li H, Lv B, Yang GY, Li ZT, Yang B.   +6 more
europepmc   +1 more source

Systematic STI screening in unaccompanied migrant minors: a 6-year experience with urine-based NAAT. [PDF]

Eur J Pediatr
Milkova-Ivanova S, Mellado-Sola I, Bravo-Queipo-de-Llano B, Rodríguez-Molino P, Grasa C, García-López-Hortelano M, Quiles-Melero I, Ruiz-Bastián MD, Maldonado-Barrueco A, Calvo C, Sainz T.   +10 more
europepmc   +1 more source